SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002165
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002165/ea020832402ex1-1_synergy.htm

Chunk 3 of 15
Word Count: 1485
Character Count: 9306

Document Content:

will be issued in compliance with all applicable securities laws, and will be free of preemptive, registration or similar rights and will conform to the description of the capital stock of the Company contained in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus. The shares of Common Stock issuable upon the exercise of the Underwriter Warrants (the “Underwriter Warrant Shares”), when issued, paid for and delivered upon due exercise of the Underwriter Warrants, as applicable, will be duly authorized and validly issued, fully paid and nonassessable, will be issued in compliance with all applicable securities laws, and will be free of preemptive, registration or similar rights. The Underwriter Warrant Shares have been reserved for issuance. The Underwriter Warrants, when issued, will conform in all material respects to the descriptions thereof set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus.

(vii)
Taxes. Each of the Company and its subsidiaries has (a) filed all foreign, federal, state and local tax returns (as hereinafter
defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing
thereof and (b) paid all taxes (as hereinafter defined) shown as due and payable on such returns that were filed and has paid all taxes
due and imposed on or assessed against the Company or such respective subsidiary, except for any taxes that are currently being contested
in good faith or that, if not paid, would not result in a Material Adverse Effect. The provisions for taxes payable, if any, shown on
the financial statements included in the Registration Statement, the Time of Sale Disclosure Package
and the Final Prospectus are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and
including the dates of such consolidated financial statements. No issues have been raised (and are currently pending) by any taxing authority
in connection with any of the returns or taxes asserted as due from the Company or its subsidiaries, and no waivers of statutes of limitation
with respect to the returns or collection of taxes have been given by or requested from the Company or its subsidiaries. The term “taxes”
mean all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatever, together with any interest and
any penalties, additions to tax, or additional amounts with respect thereto. The term “returns” means all returns,
declarations, reports, statements, and other documents required to be filed in respect to taxes.

(viii)
Material Change. Since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure
Package or the Final Prospectus, (a) neither the Company nor any of its subsidiaries has incurred any material liabilities or obligations,
direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not
declared or paid any dividends or made any distribution of any kind with respect to its capital stock; (c) there has not been any change
in the capital stock of the Company or any of its subsidiaries (other than a change in the number of outstanding shares of Common Stock
due to the issuance of shares upon the exercise of outstanding options or warrants, upon the conversion of outstanding shares of preferred
stock or other convertible securities or the issuance of restricted stock awards or restricted stock units under the Company’s
existing stock awards plan, or any new grants thereof in the ordinary course of business), (d) there has not been any material change
in the Company’s long-term or short-term debt, and (e) there has not been the occurrence of any Material Adverse Effect.

Absence of Proceedings. There is not pending or, to the knowledge of the Company, threatened, any action, suit or proceeding to
which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries
is the subject before or by any court or governmental agency, authority or body, or any arbitrator or mediator, which is reasonably likely
to result in a Material Adverse Effect

Permits. The Company and each of its subsidiaries holds, and is in compliance with, all franchises, grants, authorizations, licenses,
permits, easements, consents, certificates and orders (“Permits”) of any governmental or self-regulatory agency, authority
or body (including, without limitation, those administered by the Food and Drug Administration of the U.S. Department of Health and Human
Services (the “FDA”) or by any foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA) required for the conduct of its business as currently conducted as described in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus, and all such Permits are in full force and effect, in each case
except where the failure to hold, or comply with, any of them or the failure of any of them to be in full force and effect is not reasonably
likely to result in a Material Adverse Effect or adversely affect the consummation of the transactions contemplated by this Agreement.

Good Title. The Company and each of its subsidiaries have good and marketable title to all property (whether real or personal)
described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus as being owned by them that are
material to the business of the Company, in each case free and clear of all liens, claims, security interests, other encumbrances or
defects, except those that are disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus
and those that are not reasonably likely to result in a Material Adverse Effect. The property held under lease by the Company and its
subsidiaries is held by them under valid, subsisting and enforceable leases with only such exceptions with respect to any particular
lease as do not interfere in any material respect with the conduct of the business of the Company and its subsidiaries.

(xii)
Intellectual Property. The Company and each of its subsidiaries owns or possesses or has valid right to use all patents, patent
applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions,
trade secrets and similar rights (“Intellectual Property”) necessary for the conduct of the business of the Company
and its subsidiaries as currently carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and
the Final Prospectus. To the knowledge of the Company, no action or use by the Company or any of its subsidiaries involves or gives rise
to any infringement of, or license or similar fees for, any Intellectual Property of others, except where such action, use, license or
fee is not reasonably likely to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any
notice alleging any such infringement or fee. To the Company’s knowledge, none of the technology employed by the Company or any
subsidiary has been obtained or is being used by the Company or such subsidiary in violation of any contractual obligation binding on
the Company or such subsidiary or, to the Company’s knowledge, any of the officers, directors or employees of the Company or any
subsidiary, or, to the Company’s knowledge, otherwise in violation of the rights of any persons, except in each case for such violations
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(xiii)
Employment Matters. There is (A) no unfair labor practice complaint pending against the Company, or any of its subsidiaries, nor
to the Company’s knowledge, threatened against it or any of its subsidiaries, before the National Labor Relations Board, any state
or local labor relation board or any foreign labor relations board, and no grievance or arbitration proceeding arising out of or under
any collective bargaining agreement is so pending against the Company or any of its subsidiaries, or, to the Company’s knowledge,
threatened against it and (B) no labor disturbance by the employees of the Company or any of its subsidiaries exists or, to the Company’s
knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or
its subsidiaries, principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the
aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the
Company or any subsidiary plans to terminate employment with the Company or any such subsidiary.